BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol Hepatol 2016;13:175-85. [DOI: 10.1038/nrgastro.2015.226] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Bellet MM, Borghi M, Pariano M, Renga G, Stincardini C, D'Onofrio F, Brancorsini S, Garaci E, Costantini C, Romani L. Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis. Eur J Med Chem 2021;209:112921. [PMID: 33071052 DOI: 10.1016/j.ejmech.2020.112921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zhang M, Liu Y, Chen YG. Generation of 3D human gastrointestinal organoids: principle and applications. Cell Regen 2020;9:6. [PMID: 32588198 DOI: 10.1186/s13619-020-00040-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Coffey MJ, Ooi CY. Ode to the exocrine pancreas. J Cyst Fibros 2016;15:557-8. [PMID: 27461141 DOI: 10.1016/j.jcf.2016.07.005] [Reference Citation Analysis]
4 Emiralioglu N, Ademhan Tural D, Hizarcioglu Gulsen H, Ergen YM, Ozsezen B, Sunman B, Saltık Temizel İ, Yalcin E, Dogru D, Ozcelik U, Kiper N. Does cystic fibrosis make susceptible to celiac disease? Eur J Pediatr 2021;180:2807-13. [PMID: 33765186 DOI: 10.1007/s00431-021-04011-4] [Reference Citation Analysis]
5 Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19:758-767. [PMID: 29706374 DOI: 10.1016/s1470-2045(18)30188-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
6 Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, Macedo P, Perrin F, Whelan K, Elston C. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J 2019;7:881-8. [PMID: 31428412 DOI: 10.1177/2050640619841545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
7 Villella VR, Tosco A, Esposito S, Bona G, Raia V, Maiuri L. Mutation-specific therapies and drug repositioning in cystic fibrosis. Minerva Pediatr 2019;71. [DOI: 10.23736/s0026-4946.19.05506-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Trandafir LM, Leon MM, Frasinariu O, Baciu G, Dodi G, Cojocaru E. Current Practices and Potential Nanotechnology Perspectives for Pain Related to Cystic Fibrosis. J Clin Med 2019;8:E1023. [PMID: 31336857 DOI: 10.3390/jcm8071023] [Reference Citation Analysis]
9 van Dorst JM, Tam RY, Ooi CY. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics? Nutrients 2022;14:480. [DOI: 10.3390/nu14030480] [Reference Citation Analysis]
10 Safirstein J, Grant JJ, Clausen E, Savant D, Dezube R, Hong G. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis. J Cyst Fibros 2021;20:506-10. [PMID: 32736949 DOI: 10.1016/j.jcf.2020.07.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Filbrun AG, Lahiri T, Ren CL. Clinical Features and Complications of Cystic Fibrosis. Handbook of Cystic Fibrosis. Cham: Springer International Publishing; 2016. pp. 9-41. [DOI: 10.1007/978-3-319-32504-0_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Eschenhagen P, Schwarz C. [Many patients with cystic fibrosis have a better quality of life now]. MMW Fortschr Med 2021;163:74-81. [PMID: 33950452 DOI: 10.1007/s15006-021-9804-z] [Reference Citation Analysis]
13 Coffey MJ, Ooi CY. Paediatric pancreatic diseases. J Paediatr Child Health 2020;56:1694-701. [DOI: 10.1111/jpc.14688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Demouveaux B, Gouyer V, Gottrand F, Narita T, Desseyn J. Gel-forming mucin interactome drives mucus viscoelasticity. Advances in Colloid and Interface Science 2018;252:69-82. [DOI: 10.1016/j.cis.2017.12.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
15 Garg M, Ooi CY. The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy. Curr Gastroenterol Rep. 2017;19:6. [PMID: 28155088 DOI: 10.1007/s11894-017-0546-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
16 Moorefield EC, Blue RE, Quinney NL, Gentzsch M, Ding S. Generation of renewable mouse intestinal epithelial cell monolayers and organoids for functional analyses. BMC Cell Biol 2018;19:15. [PMID: 30111276 DOI: 10.1186/s12860-018-0165-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
17 Fawcett LK, Widger J, Henry GM, Ooi CY. Case report: Cholecystoduodenostomy for cholestatic liver disease in a premature infant with cystic fibrosis and short gut syndrome. BMC Pediatr 2019;19:78. [PMID: 30857526 DOI: 10.1186/s12887-019-1443-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Staufer K, Halilbasic E, Hillebrand P, Harm S, Schwarz S, Jaksch P, Kivaranovic D, Klepetko W, Trauner M, Kazemi-Shirazi L. Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. United European Gastroenterol J 2018;6:1049-55. [PMID: 30228893 DOI: 10.1177/2050640618778381] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional outcomes in patients with cystic fibrosis: A systematic review. J Cyst Fibros 2017;16:186-97. [PMID: 27693010 DOI: 10.1016/j.jcf.2016.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
20 Diamanti A, Calvitti G, Martinelli D, Santariga E, Capriati T, Bolasco G, Iughetti L, Pujia A, Knafelz D, Maggiore G. Etiology and Management of Pediatric Intestinal Failure: Focus on the Non-Digestive Causes. Nutrients 2021;13:786. [PMID: 33673586 DOI: 10.3390/nu13030786] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bilan N, Marefat E, Nouri-vaskeh M, Nikniaz L, Nikniaz Z. Effects of synbiotic supplementation on the pulmonary manifestations and anthropometric measurements in children with cystic fibrosis- a randomized clinical trial. European Journal of Integrative Medicine 2020;33:101027. [DOI: 10.1016/j.eujim.2019.101027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Tham A, Katz TE, Sutherland RE, Garg M, Liu V, Tong CW, Brunner R, Quintano J, Collins C, Ooi CY. Micronutrient intake in children with cystic fibrosis in Sydney, Australia. J Cyst Fibros 2020;19:146-52. [PMID: 31530443 DOI: 10.1016/j.jcf.2019.08.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Dutta D, Heo I, Clevers H. Disease Modeling in Stem Cell-Derived 3D Organoid Systems. Trends Mol Med. 2017;23:393-410. [PMID: 28341301 DOI: 10.1016/j.molmed.2017.02.007] [Cited by in Crossref: 328] [Cited by in F6Publishing: 288] [Article Influence: 65.6] [Reference Citation Analysis]
24 Garg M, Leach ST, Pang T, Needham B, Coffey MJ, Katz T, Strachan R, Widger J, Field P, Belessis Y, Chuang S, Day AS, Jaffe A, Ooi CY. Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old.J Cyst Fibros. 2018;17:109-113. [PMID: 28754328 DOI: 10.1016/j.jcf.2017.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Puccetti M, Pariano M, Renga G, Santarelli I, D'Onofrio F, Bellet MM, Stincardini C, Bartoli A, Costantini C, Romani L, Ricci M, Giovagnoli S. Targeted Drug Delivery Technologies Potentiate the Overall Therapeutic Efficacy of an Indole Derivative in a Mouse Cystic Fibrosis Setting. Cells 2021;10:1601. [PMID: 34202407 DOI: 10.3390/cells10071601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Tan SMJ, Coffey MJ, Ooi CY. Differences in clinical outcomes of paediatric cystic fibrosis patients with and without meconium ileus. J Cyst Fibros 2019;18:857-62. [PMID: 31672555 DOI: 10.1016/j.jcf.2019.09.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
27 Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, Lorenz M, Michl R, Gerber A, Lehmann T, Mainz JG. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One 2017;12:e0174463. [PMID: 28472055 DOI: 10.1371/journal.pone.0174463] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
28 Sullivan A, Hunt E, MacSharry J, Murphy DM. 'The Microbiome and the Pathophysiology of Asthma'. Respir Res 2016;17:163. [PMID: 27919249 DOI: 10.1186/s12931-016-0479-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
29 do Carmo TIT, Soares VEM, Wruck J, Dos Anjos F, de Resende E Silva DT, de Oliveira Maciel SFV, Bagatini MD. Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target. Inflamm Res 2021;70:633-49. [PMID: 33904934 DOI: 10.1007/s00011-021-01464-z] [Reference Citation Analysis]
30 Bolia R, Ooi CY, Lewindon P, Bishop J, Ranganathan S, Harrison J, Ford K, van der Haak N, Oliver MR. Practical approach to the gastrointestinal manifestations of cystic fibrosis. J Paediatr Child Health 2018;54:609-19. [PMID: 29768684 DOI: 10.1111/jpc.13921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Philp AR, Riquelme TT, Millar-Büchner P, González R, Sepúlveda FV, Cid LP, Flores CA. Kcnn4 is a modifier gene of intestinal cystic fibrosis preventing lethality in the Cftr-F508del mouse. Sci Rep 2018;8:9320. [PMID: 29915289 DOI: 10.1038/s41598-018-27465-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
32 Birimberg-Schwartz L, Wilschanski M. Cystic Fibrosis Related Gastrointestinal Manifestations - Moving Forward. J Cyst Fibros 2021;20:562-3. [PMID: 34452731 DOI: 10.1016/j.jcf.2021.07.011] [Reference Citation Analysis]
33 Bruzzese E, Raia V, Ruberto E, Scotto R, Giannattasio A, Bruzzese D, Cavicchi MC, Francalanci M, Colombo C, Faelli N, Daccò V, Magazzù G, Costa S, Lucidi V, Majo F, Guarino A. Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. Journal of Cystic Fibrosis 2018;17:375-82. [DOI: 10.1016/j.jcf.2017.10.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
34 Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, Young K, Surette MG, Gonska T. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Sci Rep. 2018;8:17834. [PMID: 30546102 DOI: 10.1038/s41598-018-36364-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
35 Hough NE, Chapman SJ, Flight WG. Gastrointestinal malignancy in cystic fibrosis. Paediatr Respir Rev 2020;35:90-2. [PMID: 32505496 DOI: 10.1016/j.prrv.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Więcek S, Chudek J, Woś H, Bożentowicz-Wikarek M, Kordys-Darmolinska B, Grzybowska-Chlebowczyk U. Serum Level of D-Lactate in Patients with Cystic Fibrosis: Preliminary Data. Dis Markers 2018;2018:5940893. [PMID: 30116405 DOI: 10.1155/2018/5940893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Halilbasic E, Fuerst E, Heiden D, Japtok L, Diesner SC, Trauner M, Kulu A, Jaksch P, Hoetzenecker K, Kleuser B, Kazemi-Shirazi L, Untersmayr E. Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition? Nutrients 2020;12:E765. [PMID: 32183316 DOI: 10.3390/nu12030765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Malagelada C, Bendezú R, Seguí S, Vitrià J, Merino X, Nieto A, Sihuay D, Accarino A, Molero X, Azpiroz F. Motor dysfunction of the gut in cystic fibrosis. Neurogastroenterology & Motility 2020;32. [DOI: 10.1111/nmo.13883] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Esteves CZ, de Aguiar Dias L, de Oliveira Lima E, de Oliveira DN, Rodrigues Melo CFO, Delafiori J, Souza Gomez CC, Ribeiro JD, Ribeiro AF, Levy CE, Catharino RR. Skin Biomarkers for Cystic Fibrosis: A Potential Non-Invasive Approach for Patient Screening. Front Pediatr 2017;5:290. [PMID: 29376041 DOI: 10.3389/fped.2017.00290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Sherrard LJ, Bell SC, Tunney MM. The role of anaerobic bacteria in the cystic fibrosis airway. Curr Opin Pulm Med 2016;22:637-43. [PMID: 27455453 DOI: 10.1097/MCP.0000000000000299] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
41 Ellery KM, Uc A. Recurrent Pancreatitis in Children: Past, Present, and Future. J Pediatr Gastroenterol Nutr 2020;70:413-6. [PMID: 31899736 DOI: 10.1097/MPG.0000000000002619] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Lazzarotto ES, Vasco JFM, Führ F, Riedi CA, Filho NAR. Systematic review on fecal calprotectin in cystic fibrosis. J Pediatr (Rio J) 2022:S0021-7557(22)00045-6. [PMID: 35523321 DOI: 10.1016/j.jped.2022.01.006] [Reference Citation Analysis]
43 van de Peppel IP, Bodewes FAJA, Verkade HJ, Jonker JW. Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. J Cyst Fibros 2019;18:313-20. [PMID: 30201330 DOI: 10.1016/j.jcf.2018.08.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
44 Villella VR, Esposito S, Ferrari E, Monzani R, Tosco A, Rossin F, Castaldo A, Silano M, Marseglia GL, Romani L, Barlev NA, Piacentini M, Raia V, Kroemer G, Maiuri L. Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis. Cell Death Dis 2019;10:258. [PMID: 30874543 DOI: 10.1038/s41419-019-1500-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
45 Marsh R, Gavillet H, Hanson L, Ng C, Mitchell-Whyte M, Major G, Smyth AR, Rivett D, van der Gast C. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)02155-X. [PMID: 34895838 DOI: 10.1016/j.jcf.2021.11.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Villella VR, Venerando A, Cozza G, Esposito S, Ferrari E, Monzani R, Spinella MC, Oikonomou V, Renga G, Tosco A, Rossin F, Guido S, Silano M, Garaci E, Chao YK, Grimm C, Luciani A, Romani L, Piacentini M, Raia V, Kroemer G, Maiuri L. A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease. EMBO J. 2019;38:pii: e100101. [PMID: 30498130 DOI: 10.15252/embj.2018100101] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
47 Park H, Kim J, Choi S, Suh HR, Moon JE, Kim D, Choi BS, Hwang SK, Kang B, Choe BH. Case report of compound CFTR variants in Korean siblings with cystic fibrosis: importance of differentiating cystic fibrosis from inflammatory bowel disease. Transl Pediatr 2021;10:3104-9. [PMID: 34976777 DOI: 10.21037/tp-21-274] [Reference Citation Analysis]
48 O'Driscoll CM, Bernkop-Schnürch A, Friedl JD, Préat V, Jannin V. Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this? Eur J Pharm Sci 2019;133:190-204. [PMID: 30946964 DOI: 10.1016/j.ejps.2019.03.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
49 Talwalkar JS, Koff JL, Lee HB, Britto CJ, Mulenos AM, Georgiopoulos AM. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis. Psychosomatics 2017;58:343-54. [PMID: 28576305 DOI: 10.1016/j.psym.2017.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
50 Coffey MJ, Garg M, Homaira N, Jaffe A, Ooi CY. A systematic cochrane review of probiotics for people with cystic fibrosis. Paediatr Respir Rev 2021;39:61-4. [PMID: 32917517 DOI: 10.1016/j.prrv.2020.06.020] [Reference Citation Analysis]
51 Maiuri L, Raia V, Piacentini M, Tosco A, Villella VR, Kroemer G. Cystic fibrosis transmembrane conductance regulator (CFTR) and autophagy: hereditary defects in cystic fibrosis versus gluten-mediated inhibition in celiac disease. Oncotarget 2019;10:4492-500. [PMID: 31321000 DOI: 10.18632/oncotarget.27037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
52 Hardouin P, Chiron R, Marchandin H, Armengaud J, Grenga L. Metaproteomics to Decipher CF Host-Microbiota Interactions: Overview, Challenges and Future Perspectives. Genes (Basel) 2021;12:892. [PMID: 34207804 DOI: 10.3390/genes12060892] [Reference Citation Analysis]
53 Abuqwider J, Altamimi M, Mauriello G. Limosilactobacillus reuteri in Health and Disease. Microorganisms 2022;10:522. [DOI: 10.3390/microorganisms10030522] [Reference Citation Analysis]
54 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
55 van de Peppel IP, Doktorova M, Berkers G, de Jonge HR, Houwen RHJ, Verkade HJ, Jonker JW, Bodewes FAJA. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. J Cyst Fibros 2019;18:286-93. [PMID: 30279125 DOI: 10.1016/j.jcf.2018.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
56 Ifrah Z, Shah Rukh A, Muhammad Nauman S, Maryam S, Rahat U. Fluorescence Quenching of Graphene Quantum Dots by Chloride Ions: A Potential Optical Biosensor for Cystic Fibrosis. Front Mater 2022;9:857432. [DOI: 10.3389/fmats.2022.857432] [Reference Citation Analysis]
57 Al Sinani S, Al-Mulaabed S, Al Naamani K, Sultan R. Cystic Fibrosis Liver Disease: Know More. Oman Med J 2019;34:482-9. [PMID: 31745411 DOI: 10.5001/omj.2019.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 De Palma FDE, Raia V, Kroemer G, Maiuri MC. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis. Diagnostics (Basel) 2020;10:E1102. [PMID: 33348555 DOI: 10.3390/diagnostics10121102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Jaudszus A, Zeman E, Jans T, Pfeifer E, Tabori H, Arnold C, Michl RK, Lorenz M, Beiersdorf N, Mainz JG. Validity and Reliability of a Novel Multimodal Questionnaire for the Assessment of Abdominal Symptoms in People with Cystic Fibrosis (CFAbd-Score). Patient 2019;12:419-28. [PMID: 30887269 DOI: 10.1007/s40271-019-00361-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
60 Coffey MJ, Low I, Stelzer-Braid S, Wemheuer B, Garg M, Thomas T, Jaffe A, Rawlinson WD, Ooi CY. The intestinal virome in children with cystic fibrosis differs from healthy controls. PLoS One 2020;15:e0233557. [PMID: 32442222 DOI: 10.1371/journal.pone.0233557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
61 Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat Rev Gastroenterol Hepatol 2019;16:497-511. [PMID: 31165788 DOI: 10.1038/s41575-019-0156-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
62 Seidler U, Nikolovska K. Slc26 Family of Anion Transporters in the Gastrointestinal Tract: Expression, Function, Regulation, and Role in Disease. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 839-72. [DOI: 10.1002/cphy.c180027] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
63 Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, Pickford R, Jaffe A, Thomas T, Ooi CY. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci Rep 2019;9:18593. [PMID: 31819107 DOI: 10.1038/s41598-019-55028-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
64 Leung DH, Yimlamai D. The intestinal microbiome and paediatric liver disease. Lancet Gastroenterol Hepatol 2017;2:446-55. [PMID: 28497760 DOI: 10.1016/S2468-1253(16)30241-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
65 Maiuri L, Villella VR, Raia V, Kroemer G. The gliadin-CFTR connection: new perspectives for the treatment of celiac disease. Ital J Pediatr 2019;45:40. [PMID: 30898172 DOI: 10.1186/s13052-019-0627-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
66 Freeman AJ, Ooi CY. Pancreatitis and pancreatic cystosis in Cystic Fibrosis. Journal of Cystic Fibrosis 2017;16:S79-86. [DOI: 10.1016/j.jcf.2017.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
67 Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochim Biophys Acta Mol Basis Dis 2019;1865:965-9. [PMID: 30071276 DOI: 10.1016/j.bbadis.2018.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]